Septerna Posts $18.9M in Third-Quarter Revenue
SEPN has more than doubled off its 52-week low of $17.55.
Summary
Septerna reported $18.9M in third-quarter revenue, the first hard top-line number for the quarter, and said its cash position of $565.2M is expected to support operating plans at least into mid-2029. The stock is trading near its 52-week high of $51.10, so expectations are already elevated heading into this print. The revenue line alone doesn't tell us the bottom line — no EPS or guidance was included in the headline, and those are what will decide the reaction. This comes days after the November 4 8-K naming SEP-204, an oral TSHR inhibitor for Graves' disease and thyroid eye disease, as a development candidate, so the pipeline story is the other half of the thesis.
At the time of this announcement, SEPN was trading at $50.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $17.55 to $51.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.